School of Medicine


Showing 21-30 of 36 Results

  • Michaela Liedtke

    Michaela Liedtke

    Associate Professor of Medicine (Hematology)

    Current Research and Scholarly Interests1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis

    2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)

    3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis

  • Sydney X. Lu

    Sydney X. Lu

    Assistant Professor of Medicine (Hematology)

    BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
    Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
    The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.

    Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
    1) normal and pathologic immunity and immunotherapy
    2) cancer biology
    3) normal and malignant hematopoiesis

  • Ravi Majeti MD, PhD

    Ravi Majeti MD, PhD

    Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia and D. K. Ludwig Professor and Professor of Medicine (Hematology)

    Current Research and Scholarly InterestsThe Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.

  • Gabriel Mannis

    Gabriel Mannis

    Associate Professor of Medicine (Hematology)

    Current Research and Scholarly InterestsMy research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.

  • Bruno Medeiros

    Bruno Medeiros

    Adjunct Clinical Associate Professor, Medicine - Hematology

    Current Research and Scholarly InterestsMy clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.

  • Ann Mullally

    Ann Mullally

    Professor of Medicine (Hematology)

    Current Research and Scholarly InterestsDr. Ann Mullally's aboratory studies the genetics, biology and therapy of myeloid blood cancers, with a focus on myeloproliferative neoplasms (MPN). Using primary human samples, mouse models, genomics, single-cell sequencing and CRISPR, as well as cellular and molecular biology, the lab has investigated the key genetic events underlying MPN pathogenesis. Dr. Mullally’s lab elucidated the mechanism by which mutant calreticulin (CALR) is oncogenic and causes MPN.